- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07683039
Thyroid Fine Needle Biopsy and Impact on Pain and Diagnostic Adequacy (THY-BPSY)
July 28, 2026 updated by: Mehmet Yağtu, MD, Izmir Ataturk Training and Research Hospital
The Effect of Using Different Needle Sizes on Patient Comfort and Pain During the Sonographically Guided Fine Needle Biopsy of Thyroid Nodules: A Randomized Controlled Trial
This randomized study compares patient pain and comfort during ultrasound-guided thyroid fine needle biopsy using 21-gauge versus 27-gauge needles.
Patients with thyroid nodules were randomly assigned to one of two needle sizes.
Pain intensity was measured immediately after the procedure using a 0-100 Visual Analog Scale.
The study was conducted at İzmir Atatürk Training and Research Hospital between January 2024 and March 2024.
The aim is to determine which needle size causes less pain and better patient comfort during the biopsy procedure.
Study Overview
Status
Completed
Conditions
Detailed Description
This prospective, randomized, single-blind clinical trial compares 21-gauge and 27-gauge needles for ultrasound-guided fine-needle biopsy of thyroid nodules.
Participants are randomly assigned in a 1:1 ratio.
The study aims to evaluate whether needle gauge affects patient pain and biopsy performance.
Detailed eligibility criteria, outcome measures, and statistical analyses are provided in their respective sections.
Study Type
Interventional
Enrollment (Actual)
159
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Izmir, Turkey (Türkiye), 35620
- İzmir Atatürk Training and Education Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Thyroid nodules requiring ultrasound-guided FNB with a maximum diameter ≥10 mm,
- Intraglandular nodules with relatively central location within the thyroid gland
Exclusion Criteria:
- Patient refusal to provide informed consent,
- History of bleeding tendency or use of anticoagulant medication,
- Substernal or subclavicular localization of the lesion in cases of large goiter.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 21-gauge needle group
Patients received ultrasound-guided thyroid fine needle biopsy using 21-gauge needle
|
4. Ultrasound-guided fine needle biopsy performed using a 21-gauge needle for thyroid nodule cytology
|
|
Experimental: 27-gauge needle group
Patients received ultrasound-guided thyroid fine needle biopsy using 27-gauge needle
|
Ultrasound-guided fine needle biopsy performed using a 27-gauge needle for thyroid nodule cytology
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain score immediately after biopsy
Time Frame: In 5 minutes after the procedure
|
Pain intensity measured using 100-mm Visual Analog Scale immediately after completion of ultrasound-guided thyroid fine needle biopsy.
Higher scores indicate worse pain
|
In 5 minutes after the procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diagnostic Adequacy Rate.
Time Frame: Time Frame: Within 14 days after biopsy
|
Percentage of biopsy specimens considered adequate for cytopathological evaluation according to the Bethesda System for Reporting Thyroid Cytopathology
|
Time Frame: Within 14 days after biopsy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 19, 2024
Primary Completion (Actual)
March 30, 2024
Study Completion (Actual)
March 31, 2024
Study Registration Dates
First Submitted
June 22, 2026
First Submitted That Met QC Criteria
July 1, 2026
First Posted (Actual)
July 6, 2026
Study Record Updates
Last Update Posted (Actual)
July 30, 2026
Last Update Submitted That Met QC Criteria
July 28, 2026
Last Verified
July 1, 2026
More Information
Terms related to this study
Other Study ID Numbers
- 0001-2024
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.